US Patent Issued to SHANDONG RUIYING PIONEER PHARMACEUTICAL on Oct. 6 for "Application of TFF2 protein and IFN-Kappa protein combination in treatment of a novel coronavirus infection" (Chinese Inventors)

ALEXANDRIA, Va., Oct. 6 -- United States Patent no. 12,751,996, issued on Oct. 6, was assigned to SHANDONG RUIYING PIONEER PHARMACEUTICAL Co. LTD (Heze, China).

"Application of TFF2 protein and IFN-Kappa protein combination in treatment of a novel coronavirus infection" was invented by Jianqing Xu (Shanghai), Xiaoyan Zhang (Shanghai), Weihui Fu (Shanghai), Songhua Yuan (Shanghai) and Yongquan He (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "A TFF2 protein and an IFN-Kappa protein are combined to treat a novel coronavirus infection. A product comprises: (a) an IFN-Kappa protein; (b) a TFF2 protein; and (c) an optional pharmaceutically acceptable carrier. Provided are an application of a combination...